Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

161.89USD
23 Jul 2019
Change (% chg)

$-0.74 (-0.46%)
Prev Close
$162.63
Open
$162.79
Day's High
$163.10
Day's Low
$161.87
Volume
612,839
Avg. Vol
674,654
52-wk High
$197.00
52-wk Low
$114.27

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  AGN.N Industry Sector
P/E (TTM): -- 29.88 32.67
EPS (TTM): -11.66 -- --
ROI: -3.08 14.90 14.49
ROE: -5.61 16.02 15.79

U.S. dominates second quarter global M&A as mega deals roll on

NEW YORK/LONDON Mega deals set the pace for mergers and acquisitions (M&A) globally in the second quarter of 2019, as large U.S. companies defied trade row jitters and seized on strong equity and debt capital markets to agree on transformative combinations.

29 Jun 2019

UPDATE 1-U.S. dominates Q2 global M&A as mega deals roll on

NEW YORK/LONDON, June 28 Mega deals set the pace for mergers and acquisitions (M&A) globally in the second quarter of 2019, as large U.S. companies defied trade row jitters and seized on strong equity and debt capital markets to agree on transformative combinations.

29 Jun 2019

US syndicated lending disappoints with lowest 2Q tally in 7 years

NEW YORK, June 28 (LPC) - US syndicated lending turned in a lackluster performance in the second quarter, amounting to the lowest 2Q total in seven years and dashing expectations for a meaningful boost to first half issuance following an already lean start to 2019.

28 Jun 2019

U.S. dominates second-quarter global M&A as mega deals roll on

NEW YORK/LONDON Mega deals set the pace for mergers and acquisitions (M&A) globally in the second quarter of 2019, as large U.S. companies defied trade row jitters and seized on strong equity and debt capital markets to agree on transformative combinations.

28 Jun 2019

U.S. dominates Q2 global M&A as mega deals roll on

NEW YORK/LONDON, June 28 Mega deals set the pace for mergers and acquisitions (M&A) globally in the second quarter of 2019, as large U.S. companies defied trade row jitters and seized on strong equity and debt capital markets to agree on transformative combinations.

28 Jun 2019

PRESS DIGEST- Wall Street Journal - June 26

June 26 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

26 Jun 2019

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

26 Jun 2019

UPDATE 7-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

June 25 Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection.

26 Jun 2019

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

26 Jun 2019

US STOCKS-Wall St dragged down by Iran tensions, trade worries; Fed in focus

* Indexes down: 0.21%, S&P 0.41%, Nasdaq 0.75% (Changes comment, adds details, updates prices)

25 Jun 2019

Earnings vs. Estimates